Literature DB >> 6487470

Vagal activity is increased during intravenous isoprenaline infusion in man.

J M Arnold, D G McDevitt.   

Abstract

Eight healthy normal subjects (19-23 years) received graded intravenous isoprenaline infusions PRE- and POST-atropine, 0.04 mg/kg i.v. The adequacy of atropinization was tested with bolus intravenous injections of phenylephrine. PRE-atropine, isoprenaline caused an increase in heart rate and systolic pressure, but a decrease in diastolic pressure with little change in mean pressure (+32.8 +/- 3.0 beats/min, +18.9 +/- 3.0 mm Hg, -13.5 +/- 1.9 mm Hg, -2.7 +/- 1.9 mg Hg respectively at isoprenaline 2 micrograms/min). POST-atropine, the increase in heart rate was enhanced, the rise in systolic pressure abolished and the falls in diastolic and mean pressures exaggerated (+47.0 +/- 2.8 beats/min, -8.9 +/- 2.9 mm Hg, -27.3 +/- 2.1 mm Hg, -21.1 +/- 1.9 mm Hg, respectively at isoprenaline 2 micrograms/min). During an isoprenaline infusion, when the heart rate and blood pressure changes are stable, there is an increase rather than a decrease in cardiac vagal tone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487470      PMCID: PMC1463660          DOI: 10.1111/j.1365-2125.1984.tb02469.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  The effect of changes in the pulmonary vascular bed produced by atropine, pulmonary engorgement, and positive-pressure breathing on diffusing and mechanical properties of the lung.

Authors:  W J DALY; J C ROSS; R H BEHNKE
Journal:  J Clin Invest       Date:  1963-07       Impact factor: 14.808

2.  Circulatory, respiratory and metabolic responses to isopropylnoradrenaline in man.

Authors:  A F COBBOLD; J GINSBURG; A PATON
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

3.  On the actions of noradrenaline, adrenaline and isopropyl noradrenaline on the arterial blood pressure, heart rate and muscle blood flow in man.

Authors:  H BARCROFT; H KONZETT
Journal:  J Physiol       Date:  1949-12-15       Impact factor: 5.182

4.  Selective blockade of adrenoceptive beta receptors in the heart.

Authors:  D Dunlop; R G Shanks
Journal:  Br J Pharmacol Chemother       Date:  1968-01

5.  Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise.

Authors:  I Brick; K J Hutchison; D G McDevitt; I C Roddie; R G Shanks
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

6.  A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol.

Authors:  C R Cleaveland; R E Rangno; D G Shand
Journal:  Arch Intern Med       Date:  1972-07

7.  Effect of age and high blood pressure on baroreflex sensitivity in man.

Authors:  B Gribbin; T G Pickering; P Sleight; R Peto
Journal:  Circ Res       Date:  1971-10       Impact factor: 17.367

8.  The methodology of blood pressure recording.

Authors:  E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

9.  Assessment of selective beta-adrenoceptor blockade in man.

Authors:  R H Briant; C T Dollery; T Fenyvesi; C F George
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

10.  Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

View more
  13 in total

1.  Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects.

Authors:  B J Lipworth; B F Tregaskis; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Racial differences in drug response: isoproterenol effects on heart rate in healthy males.

Authors:  D R Rutledge; L Cardozo; J D Steinberg
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

3.  Indirect blood pressure measurement during intravenous isoprenaline infusions.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

4.  Beta-adrenoceptors in the transplanted human heart: unaltered beta-adrenoceptor density, but increased proportion of beta 2-adrenoceptors with increasing posttransplant time.

Authors:  O E Brodde; M Khamssi; H R Zerkowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

5.  Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies.

Authors:  O E Brodde; U Konschak; K Becker; F Rüter; U Poller; J Jakubetz; J Radke; H R Zerkowski
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

6.  Beta-receptor responsiveness after desipramine treatment.

Authors:  R Pohl; G N Pandey; V K Yeragani; R Balon; J M Davis; R Berchou
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Beta-adrenergic receptor responsiveness to isoprenaline in humans: concentration-effect, as compared with dose-effect evaluation and influence of autonomic reflexes.

Authors:  A Martinsson; K Lindvall; A Melcher; P Hjemdahl
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

8.  Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.

Authors:  J M Arnold; P C O'Connor; J G Riddell; D W Harron; R G Shanks; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man.

Authors:  M J Brown; A D Struthers; J M Burrin; L Di Silvio; D C Brown
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

10.  Effects of atropine on human cardiac beta 1- and/or beta 2-adrenoceptor stimulation.

Authors:  Heike Bruck; Anke Ulrich; Stefan Gerlach; Joachim Radke; Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-21       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.